Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Head and Neck Neoplasms × durvalumab × Clear all

Phase

Phase 2 7 Phase 1/2 6 Phase 1 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 29 Lung Neoplasms 9 Small Cell Lung Carcinoma 7 Biliary Tract Neoplasms 7 Carcinoma, Hepatocellular 5 Urinary Bladder Neoplasms 4 Liver Neoplasms 4 Carcinoma 4 Small Cell Lung Carcinoma Extensive Disease 2 Recurrence 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasm Metastasis 2 Gallbladder Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Renal Cell 2 Breast Neoplasms 2 Urothelial Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Pancoast Syndrome 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Non Small Cell Lung Carcinoma NSCLC 1 Non Small Cell Lung Cancer NSCLC 1 Non - Small Cell Lung Cancer NSCLC 1 Neoplasms 1 Mesothelioma, Malignant 1 Mesothelioma 1 Locally Advanced or Metastatic EGFR T790M+ NSCLC 1

Interventions

Cisplatin 42 Radiotherapy 29 Fluorouracil 20 Cetuximab 14 pembrolizumab 10 Carboplatin 9 Paclitaxel 8 Docetaxel 7 Surgical Procedures, Operative 5 Standard of Care 5 Radiotherapy, Intensity-Modulated 5 Chemotherapy, Adjuvant 5 Methotrexate 4 Gabapentin 4 Drug Therapy 4 nimotuzumab 3 Radiotherapy, Conformal 3 Porfiromycin 3 Nivolumab 3 Bleomycin 3 Afatinib 3 epacadostat 2 Tranexamic Acid 2 Tirapazamine 2 Radiation 2 Pilocarpine 2 Pemetrexed 2 Panitumumab 2 Neoadjuvant Therapy 2 Methods 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02369874 2021-02-10

EAGLE

AstraZeneca

Phase 3 Completed

736 enrolled 26 charts

Head and Neck Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡